Abaloparatide Gains APAC Presence Through Radius-Pharmanovia Collaboration

Radius Pharmaceuticals, Inc., a subsidiary of Radius Health, Inc., has announced a significant partnership with Pharmanovia, granting exclusive rights to commercialize abaloparatide, a novel bone-forming agent, in key markets across the Asia Pacific region. This innovative treatment, marketed as TYMLOS® in the U.S., is designed to address osteoporosis in postmenopausal women and men at high risk of fractures.

A Shared Vision for Osteoporosis Care

Scott Briggs, CEO of Radius, emphasized the mutual commitment driving the collaboration:
"We are excited to work with Pharmanovia to bring abaloparatide to new global markets. This partnership allows us to extend access to this critical osteoporosis treatment, improving patient outcomes in regions where treatment options are urgently needed."

Pharmanovia’s CEO, James Burt, expressed enthusiasm about the opportunity to enhance their offerings in the APAC region:
"Expanding our portfolio with abaloparatide underscores our dedication to transforming the osteoporosis care landscape in Asia. Our strong commercial presence, especially in China, positions us to maximize the impact of this groundbreaking therapy."

Key Territories and Strategic Implications

The agreement covers a diverse range of APAC markets, including China, Singapore, Thailand, Indonesia, Vietnam, Taiwan, Hong Kong, Malaysia, Macau, and the Philippines. These regions represent significant opportunities to address unmet medical needs in osteoporosis care, where rising aging populations are driving increased prevalence of the condition.

Licensing Terms

The deal involves an upfront payment from Pharmanovia to Radius, alongside potential regulatory and commercial milestone payments. Radius will also receive tiered royalties based on net sales, ensuring an ongoing collaborative interest in the therapy’s success across these territories.

About Abaloparatide

Abaloparatide is a cutting-edge anabolic agent that stimulates bone formation, offering a much-needed option for osteoporosis patients who face a heightened risk of fractures. With its demonstrated efficacy and established market presence in the U.S., the treatment is well-positioned to address gaps in osteoporosis care across Asia.

Looking Ahead

This collaboration marks a pivotal step for both companies. For Radius, it extends the global reach of abaloparatide, aligning with its mission to address unmet needs in bone health. For Pharmanovia, it enhances their robust osteoporosis portfolio and cements their leadership in the APAC region.

Together, Radius and Pharmanovia are poised to make a meaningful impact in the fight against osteoporosis, bringing hope to millions of patients seeking effective treatments.